BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 33831272)

  • 1. Xanthenylacetic Acid Derivatives Effectively Target Lysophosphatidic Acid Receptor 6 to Inhibit Hepatocellular Carcinoma Cell Growth.
    Gnocchi D; Cavalluzzi MM; Mangiatordi GF; Rizzi R; Tortorella C; Spennacchio M; Lentini G; Altomare A; Sabbà C; Mazzocca A
    ChemMedChem; 2021 Jul; 16(13):2121-2129. PubMed ID: 33831272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel lysophosphatidic acid receptor 6 antagonists inhibit hepatocellular carcinoma growth through affecting mitochondrial function.
    Gnocchi D; Kapoor S; Nitti P; Cavalluzzi MM; Lentini G; Denora N; Sabbà C; Mazzocca A
    J Mol Med (Berl); 2020 Feb; 98(2):179-191. PubMed ID: 31863151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells.
    Sbenati RM; Zaraei SO; El-Gamal MI; Anbar HS; Tarazi H; Zoghbor MM; Mohamood NA; Khakpour MM; Zaher DM; Omar HA; Alach NN; Shehata MK; El-Gamal R
    Eur J Med Chem; 2021 Jan; 210():113081. PubMed ID: 33310290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of LPAR6 overcomes sorafenib resistance by switching glycolysis into oxidative phosphorylation in hepatocellular carcinoma.
    Gnocchi D; Kurzyk A; Mintrone A; Lentini G; Sabbà C; Mazzocca A
    Biochimie; 2022 Nov; 202():180-189. PubMed ID: 35952946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of Apoptosis in Hepatocellular Carcinoma Cell Lines by Novel Indolylacrylamide Derivatives: Synthesis and Biological Evaluation.
    Hawash M; Kahraman DC; Cetin-Atalay R; Baytas SN
    Chem Biodivers; 2021 May; 18(5):e2001037. PubMed ID: 33713038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of lysophosphatidic acid receptor 6 upregulated by the choline-deficient l-amino acid-defined diet prevents hepatocarcinogenesis in mice.
    Gnocchi D; Afonso MB; Cavalluzzi MM; Lentini G; Ingravallo G; Sabbà C; Rodrigues CMP; Mazzocca A
    Mol Carcinog; 2023 May; 62(5):577-582. PubMed ID: 36752344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A distinctive protein signature induced by lysophosphatidic acid receptor 6 (LPAR6) expression in hepatocellular carcinoma cells.
    Lippolis R; Gnocchi D; Santacroce L; Siciliano RA; Mazzeo MF; Scacco S; Sabbà C; Mazzocca A
    Biochem Biophys Res Commun; 2020 Jun; 526(4):1150-1156. PubMed ID: 32321639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of novel dibenzoxanthene derivatives and observation of apoptosis in human hepatocellular cancer cells.
    Yang HH; Liu YJ; Wang XZ
    Bioorg Chem; 2017 Jun; 72():333-344. PubMed ID: 28521246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lysophosphatidic acid receptor LPAR6 supports the tumorigenicity of hepatocellular carcinoma.
    Mazzocca A; Dituri F; De Santis F; Filannino A; Lopane C; Betz RC; Li YY; Mukaida N; Winter P; Tortorella C; Giannelli G; Sabbà C
    Cancer Res; 2015 Feb; 75(3):532-43. PubMed ID: 25589345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and antitumor activity of new derivatives of xanthen-9-one-4-acetic acid.
    Gobbi S; Rampa A; Bisi A; Belluti F; Valenti P; Caputo A; Zampiron A; Carrara M
    J Med Chem; 2002 Oct; 45(22):4931-9. PubMed ID: 12383019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 9-bis[2-(pyrrolidin-1-yl)ethoxy]-6-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}-11H-indeno[1, 2-c]quinolin-11-one (BPIQ), A Quinoline Derivative Inhibits Human Hepatocellular Carcinoma Cells by Inducing ER Stress and Apoptosis.
    Chang WT; Fong Y; Chuang SC; Chou CK; Chou HL; Yang CF; Tseng CH; Chen YL; Chiu CC
    Anticancer Agents Med Chem; 2017; 17(5):692-700. PubMed ID: 27491935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and bioactivity study of evodiamine derivatives as multifunctional agents for the treatment of hepatocellular carcinoma.
    Fan X; Deng J; Shi T; Wen H; Li J; Liang Z; Lei F; Liu D; Zhang H; Liang Y; Hao X; Wang Z
    Bioorg Chem; 2021 Sep; 114():105154. PubMed ID: 34378540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer.
    Chen X; Liu Y; Zhang L; Chen D; Dong Z; Zhao C; Liu Z; Xia Q; Wu J; Chen Y; Zheng X; Cai Y
    Eur J Med Chem; 2021 Mar; 214():113219. PubMed ID: 33618175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 5-aryl-3-thiophen-2-yl-1H-pyrazoles as a new class of Hsp90 inhibitors in hepatocellular carcinoma.
    Mohamady S; Ismail MI; Mogheith SM; Attia YM; Taylor SD
    Bioorg Chem; 2020 Jan; 94():103433. PubMed ID: 31785857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of novel 1,3,4-trisubstituted pyrazole derivatives as potential chemotherapeutic agents for hepatocellular carcinoma.
    Harras MF; Sabour R
    Bioorg Chem; 2018 Aug; 78():149-157. PubMed ID: 29567429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cytotoxic and mechanistic effects of aaptamine on hepatocellular carcinoma.
    Li QL; Zhang PP; Wang PQ; Yu HB; Sun F; Hu WZ; Wu WH; Zhang X; Chen F; Chu ZY; Zhang JP; Chen SS; Lin HW
    Anticancer Agents Med Chem; 2015; 15(3):291-7. PubMed ID: 25403168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, biological activity and multiscale molecular modeling studies of bis-coumarins as selective carbonic anhydrase IX and XII inhibitors with effective cytotoxicity against hepatocellular carcinoma.
    Kurt BZ; Dag A; Doğan B; Durdagi S; Angeli A; Nocentini A; Supuran CT; Sonmez F
    Bioorg Chem; 2019 Jun; 87():838-850. PubMed ID: 31003041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of phenyl substituted polyoxygenated xanthone derivatives as anti-hepatoma agents.
    Dai M; Yuan X; Kang J; Zhu ZJ; Yue RC; Yuan H; Chen BY; Zhang WD; Liu RH; Sun QY
    Eur J Med Chem; 2013 Nov; 69():159-66. PubMed ID: 24013415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 6-Amino-2,4,5-trimethylpyridin-3-ol and 2-amino-4,6-dimethylpyrimidin-5-ol derivatives as selective fibroblast growth factor receptor 4 inhibitors: design, synthesis, molecular docking, and anti-hepatocellular carcinoma efficacy evaluation.
    Chaudhary CL; Lim D; Chaudhary P; Guragain D; Awasthi BP; Park HD; Kim JA; Jeong BS
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):844-856. PubMed ID: 35296193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of parthenolide and 5-fluorouracil conjugates as potential anticancer agents against drug resistant hepatocellular carcinoma.
    Ding Y; Li S; Ge W; Liu Z; Zhang X; Wang M; Chen T; Chen Y; Zhang Q
    Eur J Med Chem; 2019 Dec; 183():111706. PubMed ID: 31553932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.